Microbiota, immunity and immunologically-mediated diseases
Authors:
Helena Tlaskalová Hogenová 1,2; Zuzana Jirásková Zákostelská 1; Jitka Petanová 2; Miloslav Kverka 1,3
Authors‘ workplace:
Mikrobiologický ústav AVČR, v. v. i., Praha
1; Ústav imunologie a mikrobiologie 1. LF UK a VFN v Praze
2; Ústav experimentální medicíny AVČR, v. v. i., Praha
3
Published in:
Vnitř Lék 2019; 65(2): 98-107
Category:
Overview
Each individual is colonized by broad spectrum of microbes. Recent surge of interest in microbiota across all fields of medicine was motivated by an increasing body of knowledge on how commensals influence human health. This is most notable in the gut, where most microbes reside, but microbes colonizing other niches, such as oral cavity or skin, may influence health as well. Microbiota fundamentally influences the immune system development and its perturbation, i.e. dysbiosis, is associated with many inflammatory, autoimmune and neoplastic diseases. Microbiota forms a symbiotic relationship with the host – maintaining balanced and efficient immune response and protects from colonization by pathogens. Modern medicine may benefit greatly by adopting these ideas for therapeutic or prophylactic purposes. These may include manipulation with microbiota by diet, changes in lifestyle or directly by probiotics or fecal microbiota transfer.
Keywords:
inflammation – Microbiome – mucosal immunity – probiotics
Sources
3. Young VB. The role of the microbiome in human health and disease: an introduction for clinicians. BMJ 2017; 356: j831. Dostupné z DOI: <http://dx.doi.org/10.1136/bmj.j831>.
4. Tlaskalova-Hogenova H, Kverka M, Verdu EF et al. Chapter 8 – Gnotobiology and the Study of Complex Interactions between the Intestinal Microbiota, Probiotics, and the Host. In: Mestecky J, Strober W, Russell MW et al (eds). Mucosal Immunology (4th ed). Academic Press: Boston 2015: 109–133. ISBN 978–0124158474.
6. Blaser MJ. Antibiotic use and its consequences for the normal microbiome. Science 2016; 352(6285): 544–545. Dostupné z DOI: <http://dx.doi.org/10.1126/science.aad9358>.
7. Gilbert JA, Blaser MJ, Caporaso JG et al. Current understanding of the human microbiome. Nat Med 2018; 24(4): 392–400. Dostupné z DOI: <http://dx.doi.org/10.1038/nm.4517>.
8. Butto LF, Schaubeck M, Haller D. Mechanisms of Microbe-Host Interaction in Crohn‘s Disease: Dysbiosis vs. Pathobiont Selection. Front Immunol 2015; 6: 555. Dostupné z DOI: <http://dx.doi.org/10.3389/fimmu.2015.00555>.
9. Kverka M, Tlaskalova-Hogenova H. Intestinal Microbiota: Facts and Fiction. Dig Dis 2017; 35(1–2): 139–147. Dostupné z DOI: <http://dx.doi.org/10.1159/000449095>.
20. Alexander KL, Targan SR, Elson CO. Microbiota activation and regulation of innate and adaptive immunity. Immunol Rev 2014; 260(1): 206–220. Dostupné z DOI: <http://dx.doi.org/10.1111/imr.12180>.
21. Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell 2014; 157(1): 121–141. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cell.2014.03.011>.
22. Smith PM, Howitt MR, Panikov N et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 2013; 341(6145): 569–573. Dostupné z DOI: <http://dx.doi.org/10.1126/science.1241165>.
23. Weaver CT, Elson CO, Fouser LA et al. The Th17 pathway and inflammatory diseases of the intestines, lungs, and skin. Annu Rev Pathol 2013; 8: 477–512. Dostupné z DOI: <http://dx.doi.org/10.1146/annurev-pathol-011110–130318>.
25. Palm NW, de Zoete MR, Cullen TW et al. Immunoglobulin A coating identifies colitogenic bacteria in inflammatory bowel disease. Cell 2014; 158(5): 1000–1010. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cell.2014.08.006>.
26. Kawamoto S, Maruya M, Kato LM et al. Foxp3(+) T cells regulate immunoglobulin a selection and facilitate diversification of bacterial species responsible for immune homeostasis. Immunity 2014; 41(1): 152–165. Dostupné z DOI: <http://dx.doi.org/10.1016/j.immuni.2014.05.016>.
29. Marietta EV, Murray JA, Luckey DH et al. Suppression of Inflammatory Arthritis by Human Gut-Derived Prevotella histicola in Humanized Mice. Arthritis Rheumatol 2016; 68(12): 2878–2888. Dostupné z DOI: <http://dx.doi.org/10.1002/art.39785>.
30. Li B, Selmi C, Tang R et al. The microbiome and autoimmunity: a paradigm from the gut-liver axis. Cell Mol Immunol 2018; 15(6):595–609. Dostupné z DOI: <http://dx.doi.org/10.1038/cmi.2018.7>.
31. Opazo MC, Ortega-Rocha EM, Coronado-Arrazola I et al. Intestinal Microbiota Influences Non-intestinal Related Autoimmune Diseases. Front Microbiol 2018; 9: 432. Dostupné z DOI: <http://dx.doi.org/10.3389/fmicb.2018.00432>.
36. Zhong D, Wu C, Zeng X et al. The role of gut microbiota in the pathogenesis of rheumatic diseases. Clin Rheumatol 2018; 37(1): 25–34. Dostupné z DOI: <http://dx.doi.org/10.1007/s10067–017–3821–4>.
38. Manfredo Vieira S, Hiltensperger M, Kumar V et al. Translocation of a gut pathobiont drives autoimmunity in mice and humans. Science 2018; 359(6380): 1156–1161. Dostupné z DOI: <http://dx.doi.org/10.1126/science.aar7201>.
39. Xiao L, Van‘t Land B, van de Worp W et al. Early-Life Nutritional Factors and Mucosal Immunity in the Development of Autoimmune Diabetes. Front Immunol 2017; 8: 1219. Dostupné z DOI: <http://dx.doi.org/10.3389/fimmu.2017.01219>.
40. Paun A, Yau C, Danska JS. The Influence of the Microbiome on Type 1 Diabetes. J Immunol 2017; 198(2): 590–595. Dostupné z DOI: <http://dx.doi.org/.10.4049/jimmunol.1601519.
41. Hu Y, Wong FS, Wen L. Antibiotics, gut microbiota, environment in early life and type 1 diabetes. Pharmacol Res 2017; 119: 219–226. Dostupné z DOI: <http://dx.doi.org/10.1016/j.phrs.2017.01.034
43. Burrows MP, Volchkov P, Kobayashi KS et al. Microbiota regulates type 1 diabetes through Toll-like receptors. Proc Natl Acad Sci USA 2015; 112(32): 9973–9977. Dostupné z DOI: <http://dx.doi.org/10.1073/pnas.1508740112>.
45. Wekerle H. Brain Autoimmunity and Intestinal Microbiota: 100 Trillion Game Changers. Trends Immunol 2017; 38(7): 483–497. Dostupné z DOI: <http://dx.doi.org/10.1016/j.it.2017.03.008>.
47. Fung TC, Olson CA, Hsiao EY. Interactions between the microbiota, immune and nervous systems in health and disease. Nat Neurosci 2017; 20(2): 145–155. Dostupné z DOI: <http://dx.doi.org/10.1038/nn.4476>.
48. Lukáš M. Etiologie a patogeneze idiopatických střevních zánětů. Vnitř Lék 2014; 60(7–8): 640–644.
49. de Souza HS. Etiopathogenesis of inflammatory bowel disease: today and tomorrow. Curr Opin Gastroenterol 2017; 33(4): 222–229. Dostupné z DOI: <http://dx.doi.org/10.1097/MOG.0000000000000364>.
54. Green PH, Lebwohl B, Greywoode R. Celiac disease. J Allergy Clin Immunol 2015; 135(5): 1099–1106.quiz 1107. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jaci.2015.01.044>.
55. Verdu EF, Galipeau HJ, Jabri B. Novel players in coeliac disease pathogenesis: role of the gut microbiota. Nat Rev Gastroenterol Hepatol 2015; 12(9): 497–506. Dostupné z DOI: <http://dx.doi.org/10.1038/nrgastro.2015.90>.
56. Cukrowska B, Sowinska A, Bierla JB et al. Intestinal epithelium, intraepithelial lymphocytes and the gut microbiota – Key players in the pathogenesis of celiac disease. World J Gastroenterol 2017; 23(42): 7505–7518. Dostupné z DOI: <http://dx.doi.org/10.3748/wjg.v23.i42.7505>.
57. Cenit MC, Olivares M, Codoner-Franch P et al. Intestinal Microbiota and Celiac Disease: Cause, Consequence or Co-Evolution? Nutrients 2015; 7(8): 6900–6923. Dostupné z DOI: <http://dx.doi.org/10.3390/nu7085314>.
58. Caminero A, Galipeau HJ, McCarville JL et al. Duodenal Bacteria From Patients With Celiac Disease and Healthy Subjects Distinctly Affect Gluten Breakdown and Immunogenicity. Gastroenterology 2016; 151(4): 670–683. Dostupné z DOI: <http://dx.doi.org/10.1053/j.gastro.2016.06.041>.
60. Zitvogel L, Ma Y, Raoult D et al. The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies. Science 2018; 359(6382): 1366–1370. Dostupné z DOI: <http://dx.doi.org/10.1126/science.aar6918>.
61. Tilg H, Adolph TE, Gerner RR et al. The Intestinal Microbiota in Colorectal Cancer. Cancer Cell 2018; 33(6): 954–964. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ccell.2018.03.004>.
62. Allen-Vercoe E, Jobin C. Fusobacterium and Enterobacteriaceae: important players for CRC? Immunol Lett 2014; 162(2 Pt A): 54–61. Dostupné z DOI: <http://dx.doi.org/10.1016/j.imlet.2014.05.014>.
63. Klimesova K, Kverka M, Zakostelska Z et al. Altered gut microbiota promotes colitis-associated cancer in IL-1 receptor-associated kinase M-deficient mice. Inflamm Bowel Dis 2013; 19(6): 1266–1277. Dostupné z DOI: <http://dx.doi.org/10.1097/MIB.0b013e318281330a>.
64. Tlaskalova-Hogenova H, Vannucci L, Klimesova K et al. Microbiome and colorectal carcinoma: insights from germ-free and conventional animal models. Cancer J 2014; 20(3): 217–224. Dostupné z DOI: <http://dx.doi.org/10.1097/PPO.0000000000000052>.
65. David LA, Maurice CF, Carmody RN et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 2014; 505(7484): 559–563. Dostupné z DOI: <http://dx.doi.org/10.1038/nature12820>.
67. Costalonga M, Herzberg MC. The oral microbiome and the immunobiology of periodontal disease and caries. Immunol Lett 2014; 162(2 Pt A): 22–38. Dostupné z DOI: <http://dx.doi.org/10.1016/j.imlet.2014.08.017>.
68. Kim YJ, Choi YS, Baek KJ et al. Mucosal and salivary microbiota associated with recurrent aphthous stomatitis. BMC Microbiol 2016; 16(Suppl 1): 57. Dostupné z DOI: <http://dx.doi.org/10.1186/s12866–016–0673-z>.
69. Belkaid Y, Segre JA. Dialogue between skin microbiota and immunity. Science 2014; 346(6212): 954–959. Dostupné z DOI: <http://dx.doi.org/10.1126/science.1260144>.
70. Sanford JA, Gallo RL. Functions of the skin microbiota in health and disease. Semin Immunol 2013; 25(5): 370–377. Dostupné z DOI: <http://dx.doi.org/10.1016/j.smim.2013.09.005>.
73. Findley K, Oh J, Yang J et al. Topographic diversity of fungal and bacterial communities in human skin. Nature 2013; 498(7454): 367–370. Dostupné z DOI: <http://dx.doi.org/10.1038/nature12171>.
74. Zeeuwen PL, Kleerebezem M, Timmerman HM et al. Microbiome and skin diseases. Curr Opin Allergy Clin Immunol 2013; 13(5): 514–520. Dostupné z DOI: <http://dx.doi.org/10.1097/ACI.0b013e328364ebeb>.
75. Fry L, Baker BS, Powles AV et al. Is chronic plaque psoriasis triggered by microbiota in the skin? Br J Dermatol 2013; 169(1): 47–52. Dostupné z DOI: <http://dx.doi.org/10.1111/bjd.12322>.
76. Zakostelska Z, Malkova J, Klimesova K et al. Intestinal Microbiota Promotes Psoriasis-Like Skin Inflammation by Enhancing Th17 Response. PLoS One 2016; 11(7): e0159539. Dostupné z DOI: <http://dx.doi.org/10.1371/journal.pone.0159539>.
77. Fitz-Gibbon S, Tomida S, Chiu BH et al. Propionibacterium acnes strain populations in the human skin microbiome associated with acne. J Invest Dermatol 2013; 133(9): 2152–2160. Dostupné z DOI: <http://dx.doi.org/10.1038/jid.2013.21>.
78. Holmes AD. Potential role of microorganisms in the pathogenesis of rosacea. J Am Acad Dermatol 2013; 69(6): 1025–1032. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jaad.2013.08.006>.
79. Wollina U. Microbiome in atopic dermatitis. Clin Cosmet Investig Dermatol 2017; 10: 51–56. Dostupné z DOI: <http://dx.doi.org/10.2147/CCID.S130013>.
82. Reid G. Probiotics: definition, scope and mechanisms of action. Best Pract Res Clin Gastroenterol 2016; 30(1): 17–25. Dostupné z DOI <http://dx.doi.org/10.1016/j.bpg.2015.12.001>.
83. Petschow B, Dore J, Hibberd P et al. Probiotics, prebiotics, and the host microbiome: the science of translation. Ann NY Acad Sci 2013; 1306: 1–17. Dostupné z DOI: <http://dx.doi.org/10.1111/nyas.12303>.
85. Cani PD, de Vos WM. Next-Generation Beneficial Microbes: The Case of Akkermansia muciniphila. Front Microbiol 2017; 8: 1765. Dostupné z DOI: <http://dx.doi.org/10.3389/fmicb.2017.01765>.
86. van Nood E, Vrieze A, Nieuwdorp M et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013; 368(5): 407–415. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1205037>.
87. Cammarota G, Ianiro G, Tilg H et al. European consensus conference on faecal microbiota transplantation in clinical practice. Gut 2017; 66(4): 569–580. Dostupné z DOI: <http://dx.doi.org/10.1136/gutjnl-2016–313017>.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2019 Issue 2
Most read in this issue
- Anaphylactic symptoms and anaphylactic shock
- Adverse effects of immunoglobulin therapy
- Current trends in immunosuppressive treatment
- Primary immunodeficiencies in adults